$1,318.00
This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Glaucoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Eye drops
10 Oral medications
10 Intraocular implants
12 EPIDEMIOLOGY
15 MARKETED DRUGS
21 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Nyxol for Glaucoma (November 7, 2019)
29 NCX 470 for Glaucoma (October 2, 2019)
30 Multiple Drugs/Devices for Glaucoma (June 25, 2019)
31 OTX-TP for Glaucoma (May 20, 2019)
33 KEY UPCOMING EVENTS
34 KEY REGULATORY EVENTS
34 Allergan’s Ophthalmic Implant Technology Gets Nod For Durysta
34 Aerie Pharmaceuticals files MAA for Roclanda
34 New EU Approvals
35 PROBABILITY OF SUCCESS
36 LICENSING AND ASSET ACQUISITION DEALS
36 Upjohn To Divest Three In Australia To Complete On Viatris
37 REVENUE OPPORTUNITY
39 CLINICAL TRIAL LANDSCAPE
40 Sponsors by status
41 Sponsors by phase
43 BIBLIOGRAPHY
43 Prescription information
45 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of glaucoma, 2019–28
21 Figure 2: Overview of pipeline drugs for glaucoma in the US
22 Figure 3: Pipeline drugs for glaucoma, by company
22 Figure 4: Pipeline drugs for glaucoma, by drug type
22 Figure 5: Pipeline drugs for glaucoma, by classification
29 Figure 6: Nyxol for Glaucoma (November 7, 2019): Phase II – ORION-1
30 Figure 7: NCX 470 for Glaucoma (October 2, 2019): Phase II – Dolomites
32 Figure 8: OTX-TP for Glaucoma (May 20, 2019): Phase III – vs. Placebo (First)
33 Figure 9: Key upcoming events in glaucoma
35 Figure 10: Probability of success in the glaucoma/ocular hypertension (ophthalmology) pipeline
39 Figure 11: Clinical trials in glaucoma
39 Figure 12: Top 10 drugs for clinical trials in glaucoma
40 Figure 13: Top 10 companies for clinical trials in glaucoma
40 Figure 14: Trial locations in glaucoma
41 Figure 15: Glaucoma trials status
42 Figure 16: Glaucoma trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of glaucoma, 2019–28
14 Table 2: Prevalence proportions in glaucoma, 2019–28
16 Table 3: Marketed drugs for glaucoma
24 Table 4: Pipeline drugs for glaucoma in the US
28 Table 5: Nyxol for Glaucoma (November 7, 2019)
29 Table 6: NCX 470 for Glaucoma (October 2, 2019)
30 Table 7: Multiple Drugs/Devices for Glaucoma (June 25, 2019)
31 Table 8: OTX-TP for Glaucoma (May 20, 2019)
37 Table 9: Historical global sales, by drug ($m), 2015–19
38 Table 10: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!